New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
13:43 EDTJAZZJazz Pharma sees 2012 revenue to meet or exceed prior view of $575M-$585M
Consensus $592.91M. In presentation slides for the JPMorgan Global Healthcare Conference, Jazz Pharmaceuticals stated, "The company currently expects that, for the year ended December 31, 2012, reported total revenues will meet or exceed the guidance range provided on November 8, 2012. Guidance includes EUSA Pharma contribution from June 12, 2012 and Azur Pharma contribution from January 18, 2012, and excludes the Women’s Health business, which is now accounted for as discontinued operations."
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
11:51 EDTJAZZOECD looks to close tax loopholes with new proposals
Subscribe for More Information
September 8, 2014
08:17 EDTJAZZJazz Pharmaceuticals executing on all cylinders, says Stifel
Following management meetings, Stifel reiterates its Buy rating and $195 price target on Jazz Pharmaceuticals given growth opportunities and sustainability of its current portfolio. The firm agrees with the Xyrem franchise expansion strategies through new patient capture near-term, and longer-term, the addition of complementary wakefulness products.
07:21 EDTJAZZJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information
September 5, 2014
11:40 EDTJAZZJazz Pharmaceuticals calls active on renewed takeover speculation
Subscribe for More Information
11:00 EDTJAZZRumor: Jazz Pharmaceuticals strength attributed to renewed takeover speculation
Subscribe for More Information
September 3, 2014
07:47 EDTJAZZJazz Pharmaceuticals management to meet with Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use